Resources
21 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/3/2019 (updated 3/25/2024)
Focus Group / Key informant interview sample questions
Posted 10/7/2019 (updated 3/25/2024)
It’s All About That Data (Panel Discussion) Webinar Reccording
Posted 10/7/2019 (updated 3/25/2024)
Daunting Made Doable: Selecting Evidence-Based Programs and Practices (EBPs) Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
It’s All About That Data Webinar Presentation and Materials.
Posted 2/9/2022 (updated 3/26/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. These measures are pending OMB clearance and are subject to revision. This page contains the RCORP data collection resources for the Psychostimulant Support grantees only.
These documents will be updated as new guidance or data sources are identified. We encourage you to bookmark this page so you have the latest version available. Please send any measure-related questions to your HRSA Project Officer or email: rcorp-eval@jbsinternational.com.
Posted 4/26/2023 (updated 3/27/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. This page contains the RCORP data collection resources for the MAT Access grantees.
Posted 4/26/2023 (updated 3/27/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. This page contains the RCORP data collection resources for the Behavioral Health Care Support grantees.
Posted 12/21/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration released a notice of proposed rulemaking that would allow certified opioid treatment programs to begin prescribing the drug via audio-only or video-enabled telehealth. See additional information under Policy Updates below. The proposed changes come on top of recent findings by HHS of the positive impact of its revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that removed two longstanding requirements for obtaining a waiver to treat up to 30 patients with buprenorphine: 1) the requirement for specific training, and 2) the need for otherwise eligible clinicians to certify their ability to provide or refer patients for counseling and other services. Rural primary care providers have obtained the DEA waiver at a lower rate than urban clinicians; decreased burden and greater flexibility in the guidelines, along with broader use of telehealth could help close that gap.
Posted 7/24/2020 (updated 3/28/2024)
This final rule makes changes to the Department of Health and Human Services’ (HHS) regulations governing the Confidentiality of Substance Use Disorder Patient Records. These changes were prompted by the need to continue aligning the regulations with advances in the U.S. health care delivery system, while retaining important privacy protections for individuals seeking treatment for substance use disorders (SUDs).
Posted 8/13/2020 (updated 3/28/2024)
This issue brief presents data on prevalence of opioid misuse & death rates in the Hispanic/Latino population; contextual factors & challenges to prevention & treatment; innovative outreach & engagement strategies to connect people to evidence-based treatment; and the importance of community voice.